Skip to main content

Advertisement

Table 2 Proportion of 2010-UA and 1987-UA patients progressing to RA within 1 year within groups of similar ACPA and RF status

From: Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example

  RA No RA % RA/% non-RA development (pre-test risks)a OR (95% CI) PPV (95% CI) NPV (95% CI)
1987-UA patients (n = 1352)
 ACPA–RF– (n = 929) anti-CarP+ 23 42 21/79 2.1
(1.3–3.7)
35
(25–48)
80
(77–82)
anti-CarP– 176 688
 ACPA+RF– (n = 64) anti-CarP+ 16 10 50/50 2.2
(0.8–6.1)
62
(43–78)
58
(42–72)
anti-CarP– 16 22
 ACPA–RF+ (n = 140) anti-CarP+ 8 9 39/61 1.4
(0.5–4.0)
47
(26–69)
62
(53–70)
anti-CarP– 47 76
 ACPA+RF+ (n = 219) anti-CarP+ 107 42 71/29 1.2
(0.6–2.2)
72
(64–78)
31
(22–43)
anti-CarP– 48 22
2010-UA patients (n = 838)
 ACPA–RF– (n = 755) anti-CarP+ 1 48 4/96 0.5
(0.1–3.5)
2
(0–11)
96
(94–97)
anti-CarP– 30 676
 ACPA+RF– (n = 15) anti-CarP+ 1 2 13/87 5.5
(0.2–129)
33
(6–79)
92
(65–99)
anti-CarP– 1 11
 ACPA–RF+ (n = 35) anti-CarP+ 0 4 17/83 Undefined 0
(0–49)
81
(64–91)
anti-CarP– 6 25
 ACPA+RF+ (n = 33) anti-CarP+ 9 12 42/58 1.1
(0.2–4.4)
43
(24–63)
58
(32–81)
anti-CarP– 5 7
  1. Patients were stratified according to the presence of different autoantibody combinations (ACPA–RF–, ACPA+RF–, ACPA–RF+, and ACPA+RF+); within these groups the predictive value of the presence of anticarbamylated protein (anti-CarP) antibodies for progression to rheumatoid arthritis (RA) was determined, both within 2010-undifferentiated arthritis (UA) and 1987-UA patients
  2. ACPA, anticitrullinated protein antibodies; CI, confidence interval; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value; RF, rheumatoid factor
  3. a Observed risk of RA development within ACPA and RF strata (pre-test risks), without information on anti-CarP status